RxDoctor Payments Data

David Kagey, MD

Urology · Roanoke, VANPI 1508854027

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $81,250 of the $89,541 with a category attached, or 90.7%. Roanoke Area Surgical Lasers, LLC accounts for 95.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $30,883 and has fallen 98.8% since, to $369 in 2025. Among urology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,541in general payments, 2019–2025

Across 198 payments — averaging $452.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roanoke Area Surgical Lasers, LLC$86K
  • Astellas Pharma US Inc$1K
  • Pfizer$716
  • Endo Pharmaceuticals Inc.$285
  • AbbVie$218
  • Sumitomo Pharma America, Inc.$216
  • plus $1K from 15 others

What the payments were for

  • Speaking & faculty fees$4,5005%
  • Food & beverage$3,4914%
  • Education$3010%
  • Ownership interest$81,25091%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$89,541 in reported general payments places this provider in the 95th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$292,204
Medicare patients
977
Services billed
5,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide19$443,186
MyrbetriqMirabegron45$52,861
Tamsulosin Hcl801$11,735
Testosterone22$8,867
Finasteride260$3,651
Methenamine Hippurate17$1,600
Dutasteride63$1,288
Bicalutamide20$983
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst104$913
Oxybutynin Chloride35$775
Alfuzosin Hcl ErAlfuzosin Hcl41$748
Oxybutynin Chloride ErOxybutynin Chloride28$738
Solifenacin Succinate14$567
NitrofurantoinNitrofurantoin Macrocrystal11$496
Ciprofloxacin Hcl93$347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,332$496,04764 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 urology providers in Virginia.

Other urology in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →